Multiple Myeloma

Skip to main content

FDA Oncology Update, CAR T-Cell Therapy, Multiple Myeloma

Carvykti Second BCMA-Directed CAR T-Cell Therapy FDA Approved for Multiple Myeloma

Multiple Myeloma

Phase 1/2 Study Results of BCMA x CD3 Bispecific Monoclonal Antibody REGN5458 in Patients with RRMM

Multiple Myeloma

Phase 1b TRIMM-2 Trial Results for Subcutaneous Talquetamab plus Daratumumab in Patients with RRMM

Multiple Myeloma

Subgroup Analysis of the FORTE Study by Risk Categories of Carfilzomib-Based Induction/Consolidation with or without Autologous Transplant and Lenalidomide or Carfilzomib-Lenalidomide Maintenance

Multiple Myeloma

First-Line Use of Daratumumab, Lenalidomide, and Dexamethasone Confers Survival Benefit Compared with Second-Line Use of Daratumumab-Based Regimens in Transplant-Ineligible Patients with Multiple Myeloma

Multiple Myeloma

End-of-Study Analysis of the LYRA Study of Daratumumab Maintenance Therapy Following DARA plus CyBorD Induction Therapy in MM

Multiple Myeloma

MagnetisMM-1 Trial Results of Elranatamab in Patients with RRMM

Multiple Myeloma

Isatuximab Short-Duration, Fixed-Volume Infusion plus VRd for Patients with NDMM Ineligible or with No Intent for Immediate ASCT

Multiple Myeloma

Daratumumab plus Ixazomib, Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Standard-Risk Transplant-Eligible NDMM

Multiple Myeloma

Results of the Phase 2 HOVON 143 Study of Induction Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Intermediate-Fit Patients with NDMM

1
2
3
4
5
6

Page 3 of 10
Results 21 - 30 of 98